The effect of hydration on the main adverse cardiovascular and cerebrovascular events and kidney injury in patients undergoing percutaneous coronary intervention

Objective To evaluate the prognosis of hydration therapy on patients undergoing percutaneous coronary intervention(PCI)with iodixanol. Methods A retrospective study was performed on 3 042 cases of patients who were admitted from October 2013 to October 2015.All the patients were performed observation 72 hours after operation and 30 days after discharge.According to whether the patients received hydration treatment before surgery, they were divided into the hydration group and the non-hydration group.There were 846 cases in the hydration therapy group, including 617 male cases and 229 female cases.There were 2 196 cases in the non-hydrated therapy group, including 1 596 male cases and 600 female cases.The main endpoint event of this study was major adverse cerebrovascular events(MACCE)within 72 hours after PCI.MACCE was defined as target lesion revascularization, stroke, stent thrombosis, cardiac death, and myocardial infarction.The secondary endpoint was the incidence of MACCE and the incidence of contrast induced acute kidney injury(CI-AKI)within 30 days after surgery. Results (1)Baseline data of The two groups: there were significant differences between hydration therapy group and non-hydrated therapy group in age[(61.91±10.61) years old, (63.43±10.93) years old, P 0.05). Secondary end points: 72 hours after PCI to 30 days after MACCE, hydration group 1 case(0.12%), the hydration group 5 cases(0.24%), the hydration group of myocardial infarction, 1 case(0.12%), 1 case of nonhydratable group target essel revascularization(0.05%), stent thrombosis in 1 case(0.05%), 3 cases(0.14%), cardiac death differences had no statistical significance.The incidence of CI-AKI in the two groups within 72 hours after PCI was compared[7.09%(58/846)、8.15%(175/2 196)], and the difference was not statistically significant(P=0.339). Conclusion The safety of isosmotic contrast agent iodixanol is demonstrated again in Chinese PCI population and no adverse effect is observed of hydration therapy on patient prognosis. Key words: Hydration therapy; Percutaneous coronary intervention; Major adverse cardiovascular and cerebrovascular events; Contrast-induced acute kidney injury